Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analog of human IGF-1 with a 13-amino acid extension and an arginine change at position 3. These changes reduce binding to IGF-binding proteins and may extend activity compared with native IGF-1. It is not FDA-approved and remains investigational.[1][2]
What is IGF-1 LR3?
IGF-1 LR3 stands for Long R3 Insulin-like Growth Factor-1. It is a lab-made analog of native IGF-1, a hormone-like growth factor involved in growth, metabolism, and tissue repair signaling.[1][4]
The “LR3” part refers to two design changes: a longer 13-amino acid extension at one end and an arginine substitution at position 3. These changes were developed to reduce binding to IGF-1 binding proteins, also called IGFBPs, which normally control how much free IGF-1 is active in the body.[1][2]
IGF-1 LR3 is different from mecasermin, the FDA-approved recombinant human IGF-1 product sold as Increlex. Mecasermin is approved only for specific severe pediatric growth disorders, and its label warns about hypoglycemia, tonsil enlargement, intracranial hypertension, and possible neoplasia concerns.[3]
How is IGF-1 LR3 different from natural IGF-1?
Native IGF-1 is insulin-like growth factor 1, a natural signal made mostly in the liver after growth hormone stimulation. Most circulating IGF-1 is bound to IGF-binding proteins, which help control its delivery, half-life, and activity in tissues.[2][4]
The 13-amino acid N-terminal extension
Long R3 IGF-1 includes a 13-amino acid extension at the N-terminus. This extension helps lower its binding to IGFBPs, which can increase free receptor activity in lab models compared with native IGF-1.[1][2]
The arginine-for-glutamic-acid swap at position 3
The “R3” change means arginine replaces glutamic acid at position 3. This change also reduces IGFBP binding while preserving activity at the IGF-1 receptor in experimental systems.[1][2]
Why the half-life is often described as 20–30 hours instead of minutes
You may see 20–30 hours quoted as the IGF-1 LR3 half-life. That number is commonly used in peptide education and product materials, but human pharmacokinetic studies are limited. The stronger evidence is that LR3 binds IGFBPs less strongly, which can prolong biological activity in experimental systems compared with unmodified IGF-1.[1][2]
How does IGF-1 LR3 work in the body?
IGF-1 LR3 is designed to activate the IGF-1 receptor, a cell-surface receptor involved in growth and metabolism. This receptor can trigger PI3K/Akt and MAPK signaling, two pathways linked with protein synthesis, cell survival, and cell growth.[4][7]
Binding to the IGF-1 receptor
When IGF-1 binds the IGF-1 receptor, it starts a signal inside the cell. IGF-1 LR3 appears to keep this receptor activity while binding less to IGFBPs, which is why it may act more strongly in lab systems.[1][2][4]
PI3K/Akt and MAPK signaling
The PI3K/Akt pathway is involved in glucose handling, protein synthesis, and cell survival. The MAPK pathway is involved in cell growth and division. These same pathways are why safety questions matter: growth signals can be helpful in normal repair, but they may be risky in settings where abnormal cells are present.[4][5][7]
Effects on muscle, fat, and glucose metabolism
IGF-1 signaling is linked with muscle protein balance, satellite cell activity, and glucose metabolism in human biology. But a signal that can support growth can also lower blood sugar, affect insulin sensitivity, and raise concern in people with active cancer, past cancer, or unexplained growths.[3][5][8]
What are the potential benefits people report?
IGF-1 LR3 benefits discussed online often include muscle growth, workout recovery, body recomposition, and tissue repair. These claims are mostly based on the biology of IGF-1 signaling, animal or lab data, and non-medical use reports—not large, high-quality human trials of IGF-1 LR3 for wellness, performance, or anti-aging.[1][2][4]
Muscle growth and recovery
IGF-1 is involved in muscle growth pathways and satellite cell activity, which is why IGF-1 LR3 is discussed in bodybuilding and recovery circles. The trade-off is that IGF-1-type activity may also cause low blood sugar, swelling, joint discomfort, and growth-signal concerns in people with cancer risk.[3][5][8]
Body composition and fat metabolism
Because IGF-1 sits in the growth hormone–IGF-1 axis, some people use it for body composition goals. But IGF-1 activity can interact with insulin and glucose metabolism, and higher IGF signaling has been studied in relation to cancer biology, so benefits should not be viewed apart from these risks.[5][7][9]
Tissue repair and skin
IGF-1 signaling is part of normal tissue repair biology. Still, IGF-1 LR3 is not approved for wound healing, skin rejuvenation, or anti-aging, and growth-factor stimulation may be unsafe without specialist review in people with active malignancy, prior cancer, or suspicious lesions.[3][5]
What does the actual clinical evidence show?
IGF-1 LR3 has a much thinner human evidence base than approved medicines. Published work supports its altered receptor and binding-protein behavior in experimental settings, but there are not large FDA-reviewed trials proving safety and effectiveness for muscle gain, fat loss, longevity, or recovery in adults.[1][2][3]
The closest FDA-approved comparison is mecasermin, which is recombinant human IGF-1. Mecasermin is approved for severe primary IGF-1 deficiency and growth hormone gene deletion with neutralizing antibodies, not for general wellness, bodybuilding, or age-related decline.[3]
This matters because the mecasermin label shows what can happen when IGF-1 activity is used as a drug: hypoglycemia is a key warning, and the label also discusses lymphoid tissue enlargement, intracranial hypertension, slipped capital femoral epiphysis, and malignancy precautions.[3]
What are the risks and side effects of IGF-1 LR3?
IGF-1 LR3 side effects are not fully defined because it lacks an FDA-approved label and large human safety trials. Risks are inferred from IGF-1 biology, mecasermin labeling, and the known role of IGF signaling in metabolism and cell growth.[3][5][7]
Hypoglycemia and insulin resistance
IGF-1 activity can lower blood sugar, and hypoglycemia is a major warning for mecasermin. People using insulin, sulfonylureas, or other glucose-lowering medications may be at higher risk and need clinician oversight; IGF-axis changes may also interact with insulin resistance over time.[3][7]
Fluid retention and joint discomfort
Growth-factor and growth-hormone-axis therapies can be linked with swelling, soft-tissue effects, and joint or nerve discomfort. These symptoms are not proof that IGF-1 LR3 is working, and they should not be ignored because they may reflect excess growth-factor activity or another medical problem.[3][10]
Concerns about cell proliferation and cancer risk
IGF-1 receptor signaling supports cell survival and proliferation. That is why growth-factor stimulation carries a theoretical cancer-promotion risk, especially for people with active cancer, prior cancer, strong cancer risk, or unexplained lumps or lesions. Specialist review is important before any exposure to IGF-type agents.[5][9]
Sports and anti-doping status
IGF-1 and related growth factors are prohibited by the World Anti-Doping Agency. Athletes subject to WADA or sport governing-body rules should assume IGF-1 LR3 is banned unless their governing body provides written guidance.[6]
How is IGF-1 LR3 typically administered?
IGF-1 LR3 dosing and injection details online are often shared in bodybuilding or research-use settings, but this article does not provide dosing instructions. IGF-1 LR3 is not FDA-approved, and many products sold online are not labeled for human use.[3]
In clinical medicine, approved peptide or protein drugs are prescribed with specific diagnosis, monitoring, storage, and administration rules. For example, mecasermin has label instructions and warnings because blood sugar changes can be serious.[3]
If someone is considering an IGF-axis medication or peptide, a clinician would usually review goals, medications, glucose history, cancer history, family history, labs, and safer approved options. Individual results vary, and no peptide should be expected to guarantee muscle gain, fat loss, recovery, or longevity.
How does IGF-1 LR3 compare with ipamorelin, tesamorelin, and mecasermin?
IGF-1 LR3 vs ipamorelin is not an apples-to-apples comparison. IGF-1 LR3 is an IGF-1 analog, while ipamorelin is a growth hormone secretagogue studied for GH release; tesamorelin is an FDA-approved growth hormone-releasing hormone analog for HIV-associated lipodystrophy; mecasermin is FDA-approved recombinant human IGF-1 for rare pediatric growth disorders.[3][10][11]
| Option | What it is | FDA status | Main evidence-backed use | Key safety issues |
|---|---|---|---|---|
| IGF-1 LR3 | Synthetic Long R3 IGF-1 analog with reduced IGFBP binding | Not FDA-approved for human use | Investigational; no approved medical indication | Hypoglycemia, glucose effects, swelling, joint discomfort, theoretical cancer-promotion risk |
| Native IGF-1 | Natural insulin-like growth factor 1 made in the GH–IGF-1 axis | Not used as a stand-alone consumer drug | Normal growth and metabolic signaling in the body | Excess or abnormal signaling may affect glucose and cell growth |
| Mecasermin / Increlex | Recombinant human IGF-1 | FDA-approved | Severe primary IGF-1 deficiency and limited pediatric indications | Hypoglycemia, lymphoid tissue growth, intracranial hypertension, malignancy precautions |
| Ipamorelin | Growth hormone secretagogue peptide | Not FDA-approved | Studied for GH release; not approved for anti-aging or muscle gain | Limited human indication data, possible GH-axis effects, glucose and fluid concerns |
| Tesamorelin / Egrifta SV | Growth hormone-releasing hormone analog | FDA-approved | Reduction of excess abdominal fat in adults with HIV and lipodystrophy | Glucose intolerance, fluid retention, malignancy-related precautions |
Tesamorelin has an FDA-approved use, but that does not mean it is approved for general fat loss or longevity. Its label includes warnings about malignancy, glucose intolerance, fluid retention, and hypersensitivity.[10]
Is IGF-1 LR3 legal? Is it FDA-approved?
IGF-1 LR3 is not FDA-approved for any human use. That means there is no FDA-reviewed prescribing label for dosing, purity, manufacturing, safety, or effectiveness in patients.[3]
Products sold online as “research use only” are not the same as FDA-approved medicines. They may not meet drug-quality standards for human use, and patients may not know the true identity, strength, sterility, or contaminants in a vial.
Compounded IGF-1 LR3 via a 503A pharmacy would still not be FDA-approved. A 503A pharmacy is a state-licensed pharmacy that may compound patient-specific prescriptions under federal and state rules, but compounded drugs do not go through FDA premarket approval for safety or effectiveness.[12]
How can you access IGF-1 LR3 through a licensed clinician?
The safest first step is not to buy IGF-1 LR3 online. It is to ask a licensed clinician whether an IGF-axis evaluation is appropriate, whether approved options exist, and whether any peptide discussion is legal and medically reasonable for your situation.[3][12]
A clinician may review symptoms, medical history, glucose labs, IGF-1 levels, cancer history, medications, and goals. They may also explain why IGF-1 LR3 is not appropriate, or why an FDA-approved treatment such as mecasermin or tesamorelin applies only to narrow diagnoses.[3][10]
Chia is one telehealth option for clinician-reviewed access to eligible compounded GLP-1 medications and longevity-peptide care through licensed pharmacy partners; IGF-1 LR3 availability depends on current law, clinical fit, and pharmacy status, and is never guaranteed.
3-min quiz
Want a clinician-reviewed peptide conversation?
Learn what options may be appropriate based on your health history, goals, and current regulations.
Frequently asked questions about IGF-1 LR3
IGF-1 LR3 is a synthetic version of insulin-like growth factor 1. It was modified to bind less strongly to IGF-binding proteins, which may make its signaling last longer in experimental systems. It is not FDA-approved for human use.[1][2][3]
No. IGF-1 LR3 is not FDA-approved for any human use. Mecasermin, a different recombinant human IGF-1 product, is FDA-approved only for specific severe pediatric growth disorders.[3]
Many peptide sources cite about 20–30 hours, but strong human pharmacokinetic data are limited. The better-supported point is that Long R3 IGF-1 binds IGF-binding proteins less strongly than native IGF-1, which can extend biological activity in experimental systems.[1][2]
The main concerns are low blood sugar, glucose and insulin effects, swelling, joint discomfort, and theoretical cancer-promotion risk because IGF-1 receptor signaling can support cell growth. People with active cancer, prior cancer, or unexplained lesions need specialist review.[3][5][7]
Yes. IGF-1 and related growth factors are prohibited under the WADA Prohibited List. Athletes should not use IGF-1 LR3 unless their sport authority gives clear written guidance.[6]
There is no FDA-approved treatment timeline for IGF-1 LR3 because it is not an approved medicine. Reports online vary, and individual results vary. Any perceived benefit must be weighed against safety and legal concerns.[3]
A clinician can discuss the IGF-1 axis, order appropriate tests, and review legal options. IGF-1 LR3 itself is not FDA-approved, and any compounded use would depend on federal and state rules, patient-specific need, and pharmacy compliance.[3][12]
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still decides whether any treatment is appropriate.
3-min quiz
Talk with a licensed clinician
If you are exploring peptides, start with a medical review—not a research-use vial. A clinician can help you understand risks, legal status, and safer alternatives.
References
- 1.Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. Novel recombinant fusion protein analogues of insulin-like growth factor-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology. 1992.
- 2.Ballard FJ, Wallace JC, Francis GL. Long R3 insulin-like growth factor-I: a potent analogue of insulin-like growth factor-I. International Journal of Biochemistry & Cell Biology. 1996.
- 3.U.S. Food and Drug Administration. Increlex (mecasermin) prescribing information. FDA label. 2024.
- 4.LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews. 1995.
- 5.Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer. 2008.
- 6.World Anti-Doping Agency. The 2026 Prohibited List: International Standard. 2026.
- 7.Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001.
- 8.Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocrine Reviews. 1996.
- 9.Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. The Lancet. 1998.
- 10.U.S. Food and Drug Administration. Egrifta SV (tesamorelin) prescribing information. FDA label. 2024.
- 11.Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998.
- 12.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA. 2024.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
